Gilead Offers Up $4.3bn For CymaBay And Phase III PBC Candidate

Adding to its liver disease portfolio, Gilead agreed to pay a 27% premium for CymaBay and seladelpar, which has a 14 August FDA action date to compete in second-line primary biliary cholangitis.